ClinicalTrials.gg
CompletedNCT05248867Updated May 24, 2024Results posted

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

A Phase 3 interventional study of Placebo and AGN-151586 in Glabellar Lines, sponsored by AbbVie. Completed at 38 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
638
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study was to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in participants with moderate to severe GL.

This was a 12-week study in which eligible subjects were enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants were randomly assigned to receive AGN-151586 or placebo. There was 1 in a 4 chance that participants would receive placebo. Around 600 adult participants with moderate to severe GL were to be enrolled in the study in approximately 38 sites across the world.

Participants received either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may have received an open-label treatment of AGN-151586 during the study.

Participants attended regular visits during the study at a study site. The effect of the treatment was checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.

02

Conditions studied

  • Glabellar Lines

Keywords

  • Glabellar Lines
  • AGN-151586
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to accurately assess their facial lines without the use of eyeglasses (contact lens use is acceptable).
  • Participant must have moderate or severe Glabellar Lines at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS) at Screening and Baseline Day 1 visit.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled systemic disease.
  • Presence or history of any medical condition that may place the participant at increased risk following exposure to AGN-151586 or interfere with the study evaluation, including:

    • Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
    • History of facial nerve palsy
    • Infection or dermatological condition at the treatment injection sites
    • Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, excessively photodamaged skin, or the inability to substantially lessen facial lines even by physically spreading them apart
    • Any eyebrow or eyelid ptosis at screening or Baseline Day 1 visit as determined by the investigator
  • History of known immunization to any botulinum neurotoxin serotype.
  • Participants who have reported use of any botulinum neurotoxin of any serotype (including any botulinum neurotoxin product) for aesthetic treatment within the last 6 months prior to Baseline (Day 1 of treatment) and for therapeutic treatment within the last 12 months prior to study drug administration.
  • Tattoos, jewelry, or clothing which obscure the glabellar area and cannot be removed.
  • Anticipated need for surgery or overnight hospitalization during the study.
  • History of surgical procedures on forehead and/or periorbital areas or affecting these areas including any lifting procedure (e.g., rhinoplasty, facial lift, suture lift, thread lift, brow lift, eyelid and/or eyebrow surgery).
  • History of periorbital, mid-facial, or upper-facial treatment with semi-permanent or permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide, polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation and/or autologous fat transplantation.
  • Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • Female participant who is pregnant or breastfeeding, and is considering becoming pregnant or donating eggs during the study or for approximately 30 days after the last dose of study drug or until the end of study, whichever is longer.
  • Participant who has been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study or was previously enrolled in this study.
  • Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study drug).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
638 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received 5 intramuscular injections of placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participants may have also received 1 open-label treatment of AGN-151586 on Day 43.

    Drug: Placebo · Drug: AGN-151586

  • Experimental
    AGN-151586

    Participants received 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, participants may also have received 1 open-label treatment of AGN-151586 on Day 43.

    Drug: AGN-151586

Interventions

  • DrugPlacebo

    Placebo solution for injection

  • AGN-151586 solution for injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]

    \[Primary endpoint for the United States FDA\] Percentage of participants achieving a Grade 0 or 1 (none or mild) and a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to both investigator and participant assessments of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind period)

  2. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]

    \[Primary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind period)

  3. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]

    \[Primary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind Period)

  4. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: From time of informed consent to end of study; median time on follow-up was 85 days for Double-blind Placebo, AGN-151586, Open-label Placebo/AGN-151586 and AGN-151586/AGN-151586 groups, 50 days for Placebo/None group, and 53 days for AGN-151586/None group

Secondary outcomes

  1. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Participant Assessments of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

    \[Secondary endpoint for the United States FDA\] Percentage of participants achieving a Grade 0 or 1 (none or mild) and a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to both investigator and participant assessments of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)

  2. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

    \[Secondary endpoint for the United States FDA\] Percentage of participants with a Grade 0 or 1 (none or mild) and at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)

  3. Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

    \[Secondary endpoint for the United States FDA\] Percentage of participants with a Grade 0 or 1 (none or mild) and at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)

  4. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Day 7 [US FDA]

    \[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Day 7 (Double-blind Period)

  5. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [United States FDA]

    \[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Hour 24 (Double-blind Period)

  6. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [US FDA]

    \[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their satisfaction with natural look using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Day 7 (Double-blind Period)

  7. Percentage of Participants With a ≥ 20-point Improvement From Baseline in FLO-11 Total Scores for GL at Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind Period)

  8. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hour 24 (Double-blind Period)

  9. Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Hour 24 during the Double-Blind Period are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hour 24 (Double-blind Period)

  10. Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hour 24 (Double-blind Period)

  11. Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hour 24 (Double-blind Period)

  12. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Hour 24 (Double-blind Period)

  13. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their satisfaction with natural look using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Day 7 (Double-blind Period)

  14. Time to the First ≥ 1-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Time to the first ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown is reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. For those who did not improve at least 1 grade from Baseline, censoring occurred at the latest visit during the treatment period for which FWS data were available.

    Time frame: From Baseline to Day 43 (Double-blind Period)

  15. Time to the First ≥1-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Time to the first ≥1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown is reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. For those who did not improve at least 1 grade from Baseline, censoring occurred at the latest visit during the treatment period for which FWS data were available.

    Time frame: From Baseline to Day 43 (Double-blind Period)

  16. Percentage of Participants With ≥2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown Over Time [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind period)

  17. Percentage of Participants With ≥2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown Over Time [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind period)

  18. Time to Return to Baseline FWS According to Participant Assessment of FWS at Maximum Frown After Achieving Responder Definition on Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Time to return to Baseline (Baseline criterion of Moderate or Severe) on the Facial Wrinkle Scale (FWS) according to participant assessment of FWS at maximum frown after achieving responder definition on Day 7 is reported. Responder definition was a rating of None or Mild on the FWS. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. For those who maintained their response, censoring occurred at the latest visit during the treatment period for which FWS was available.

    Time frame: From Baseline to Day 43 (Double-blind Period)

  19. Time to Return to Baseline FWS According to Investigator Assessment of FWS at Maximum Frown After Achieving Responder Definition on Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] Time to return to Baseline (Baseline criterion of Moderate or Severe) on the Facial Wrinkle Scale (FWS) according to investigator assessment of FWS at maximum frown after achieving responder definition on Day 7 is reported. Responder definition was a rating of None or Mild on the FWS. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. For those who maintained their response, censoring occurred at the latest visit during the treatment period for which FWS was available.

    Time frame: From Baseline to Day 43 (Double-blind Period)

  20. Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL Over Time [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Hours 8, 24, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)

  21. Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 10 (Look Angry) for GL at Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Participants answered FLO-11 Item 10 (Look Angry). Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind Period)

  22. Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 5 (Look Less Attractive) for GL at Day 7 [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Participants answered FLO-11 Item 5 (Look Less Attractive). Percentages are rounded off to nearest single decimal.

    Time frame: Baseline, Day 7 (Double-blind Period)

  23. Mean Global Assessment of Change in Glabellar Lines (GAC-GL) at Maximum Frown Over Time [European Union Regulatory Agencies]

    \[Secondary endpoint for European Union regulatory agencies\] The GAC-GL Questionnaire assesses the appearance of the participant's GL "now" in comparison with their perspective before treatment. Participants assessed the change in their glabellar lines at maximum frown using a 7-point verbal descriptor scale (VDS): very much improved, much improved, minimally improved, no change, minimally worse, much worse, and very much worse, ranging from 3 to -3. Positive changes indicate improvement, 0 no change, and negative changes indicate worsening.

    Time frame: Hours 24 and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)

07

Results

Posted May 24, 2024

Participant flow

Double-blind Period
Participant flow — Double-blind Period
MilestonePlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
Started1564820000
Completed1484540000
Not completed8280000
Withdrew: Lost to follow-up030000
Withdrew: Withdrawal by subject5140000
Withdrew: Withdrawal by subject due to adverse event030000
Withdrew: Other, not specified380000
Open-label Period
Participant flow — Open-label Period
MilestonePlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
Started00314517437
Completed0001430426
Not completed00321711
Withdrew: Withdrawal by subject003179
Withdrew: Withdrawal by subject due to adverse event000100
Withdrew: Lost to follow-up000052
Withdrew: Covid-19 infection000010
Withdrew: Other, not specified000040

Outcome measures

PrimaryPercentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]

\[Primary endpoint for the United States FDA\] Percentage of participants achieving a Grade 0 or 1 (none or mild) and a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to both investigator and participant assessments of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind period)
Reported as:
Number · percentage of participants
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA]0.6 (0.0 to 1.9)60.0 (55.5 to 64.4)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 59.3 · 95% CI 54.7 to 63.9Difference: AGN-151586 - Placebo
PrimaryPercentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]

\[Primary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]0.8 (0.0 to 2.3)61.0 (55.9 to 66.0)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 60.2 · 95% CI 54.9 to 65.4Difference: AGN-151586 - Placebo
PrimaryPercentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]

\[Primary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Day 7 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [European Union Regulatory Agencies]0.8 (0.0 to 2.3)72.1 (67.5 to 76.7)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 71.4 · 95% CI 66.5 to 76.2Difference: AGN-151586 - Placebo
PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

Time frame:
From time of informed consent to end of study; median time on follow-up was 85 days for Double-blind Placebo, AGN-151586, Open-label Placebo/AGN-151586 and AGN-151586/AGN-151586 groups, 50 days for Placebo/None group, and 53 days for AGN-151586/None group
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
Any TEAE44118032090
TESAE130001
SecondaryPercentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Participant Assessments of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

\[Secondary endpoint for the United States FDA\] Percentage of participants achieving a Grade 0 or 1 (none or mild) and a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to both investigator and participant assessments of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Participant Assessments of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]
percentage of participantsPlaceboAGN-151586
Hour 80.0 (0.0 to 0.0)7.1 (4.8 to 9.3)
Hour 120.6 (0.0 to 1.9)15.9 (12.6 to 19.2)
Hour 240.6 (0.0 to 1.9)30.4 (26.3 to 34.6)
Hour 360.6 (0.0 to 1.9)43.2 (38.7 to 47.6)
Hour 480.6 (0.0 to 1.9)50.1 (45.6 to 54.6)
Day 70.6 (0.0 to 1.9)60.0 (55.5 to 64.4)
Day 140.0 (0.0 to 0.0)25.3 (21.4 to 29.2)
Day 210.0 (0.0 to 0.0)2.7 (1.3 to 4.2)
Day 280.0 (0.0 to 0.0)0.2 (0.0 to 0.6)
Day 350.0 (0.0 to 0.0)0.4 (0.0 to 1.0)
Day 430.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

\[Secondary endpoint for the United States FDA\] Percentage of participants with a Grade 0 or 1 (none or mild) and at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]
percentage of participantsPlaceboAGN-151586
Hour 81.3 (0.0 to 3.0)11.0 (8.2 to 13.8)
Hour 120.7 (0.0 to 2.0)20.2 (16.6 to 23.8)
Hour 240.6 (0.0 to 1.9)37.4 (33.1 to 41.8)
Hour 360.7 (0.0 to 2.0)53.1 (48.6 to 57.6)
Hour 480.6 (0.0 to 1.9)62.2 (57.9 to 66.6)
Day 70.6 (0.0 to 1.9)72.6 (68.6 to 76.6)
Day 140.0 (0.0 to 0.0)32.3 (28.1 to 36.6)
Day 210.0 (0.0 to 0.0)5.2 (3.2 to 7.3)
Day 280.0 (0.0 to 0.0)1.3 (0.3 to 2.2)
Day 350.0 (0.0 to 0.0)0.4 (0.0 to 1.0)
Day 430.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]

\[Secondary endpoint for the United States FDA\] Percentage of participants with a Grade 0 or 1 (none or mild) and at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of Glabellar Lines (GL) Severity at Maximum Frown Over Time [US FDA]
percentage of participantsPlaceboAGN-151586
Hour 80.0 (0.0 to 0.0)8.1 (5.7 to 10.5)
Hour 120.7 (0.0 to 2.0)18.5 (15.0 to 22.0)
Hour 240.6 (0.0 to 1.9)32.1 (27.9 to 36.3)
Hour 360.6 (0.0 to 1.9)44.4 (40.0 to 48.9)
Hour 481.9 (0.0 to 4.1)51.8 (47.3 to 56.3)
Day 70.6 (0.0 to 1.9)63.3 (58.9 to 67.6)
Day 140.0 (0.0 to 0.0)29.8 (25.6 to 34.0)
Day 210.0 (0.0 to 0.0)4.2 (2.4 to 6.1)
Day 280.0 (0.0 to 0.0)1.9 (0.7 to 3.1)
Day 351.3 (0.0 to 3.0)1.2 (0.3 to 2.2)
Day 430.0 (0.0 to 0.0)0.8 (0.0 to 1.7)
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Day 7 [US FDA]

\[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Day 7 [US FDA]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Day 7 [US FDA]5.1 (1.7 to 8.6)77.6 (73.9 to 81.4)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 72.5 · 95% CI 67.4 to 77.6Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [United States FDA]

\[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [United States FDA]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [United States FDA]17.3 (11.4 to 23.2)59.2 (54.8 to 63.6)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 41.9 · 95% CI 34.5 to 49.3Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [US FDA]

\[Secondary endpoint for the United States FDA\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their satisfaction with natural look using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [US FDA]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [US FDA]9.0 (4.5 to 13.5)78.5 (74.8 to 82.2)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 69.5 · 95% CI 63.7 to 75.3Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 20-point Improvement From Baseline in FLO-11 Total Scores for GL at Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 20-point Improvement From Baseline in FLO-11 Total Scores for GL at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 20-point Improvement From Baseline in FLO-11 Total Scores for GL at Day 7 [European Union Regulatory Agencies]8.5 (3.7 to 13.2)66.6 (61.8 to 71.5)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 58.2 · 95% CI 51.3 to 65.0Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]0.8 (0.0 to 2.3)30.9 (26.2 to 35.7)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 30.1 · 95% CI 25.2 to 35.1Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Hour 24 during the Double-Blind Period are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]0.8 (0.0 to 2.3)36.5 (31.5 to 41.4)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 35.7 · 95% CI 30.5 to 40.9Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Participant Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]11.5 (6.0 to 17.0)64.1 (59.2 to 69.1)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 52.6 · 95% CI 45.2 to 60.0Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with a ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown at Hour 24 are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 1-grade Improvement From Baseline on FWS According to Investigator Assessment of GL Severity at Maximum Frown at Hour 24 [European Union Regulatory Agencies]13.8 (7.9 to 19.8)72.5 (67.9 to 77.1)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 58.6 · 95% CI 51.1 to 66.1Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Hour 24 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL at Hour 24 [European Union Regulatory Agencies]16.2 (9.8 to 22.5)58.7 (53.6 to 63.7)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 42.5 · 95% CI 34.4 to 50.6Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their satisfaction with natural look using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 4 (Natural Look) for GL at Day 7 [European Union Regulatory Agencies]7.7 (3.1 to 12.3)77.7 (73.3 to 82.0)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 70.0 · 95% CI 63.7 to 76.3Difference: AGN-151586 - Placebo
SecondaryTime to the First ≥ 1-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Time to the first ≥ 1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown is reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. For those who did not improve at least 1 grade from Baseline, censoring occurred at the latest visit during the treatment period for which FWS data were available.

Time frame:
From Baseline to Day 43 (Double-blind Period)
Reported as:
Median · days
Time to the First ≥ 1-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown [European Union Regulatory Agencies]
daysPlaceboAGN-151586
Time to the First ≥ 1-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown [European Union Regulatory Agencies]41.9 (0 to 69)1.0 (0 to 45)
SecondaryTime to the First ≥1-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Time to the first ≥1-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown is reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. For those who did not improve at least 1 grade from Baseline, censoring occurred at the latest visit during the treatment period for which FWS data were available.

Time frame:
From Baseline to Day 43 (Double-blind Period)
Reported as:
Median · days
Time to the First ≥1-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown [European Union Regulatory Agencies]
daysPlaceboAGN-151586
Time to the First ≥1-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown [European Union Regulatory Agencies]41.0 (0 to 69)0.7 (0 to 45)
SecondaryPercentage of Participants With ≥2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown Over Time [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to participant assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind period)
Reported as:
Number · percentage of participants
Percentage of Participants With ≥2-grade Improvement From Baseline on the FWS According to Participant Assessment of GL Severity at Maximum Frown Over Time [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Hour 80.0 (0.0 to 0.0)7.6 (4.9 to 10.3)
Hour 120.8 (0.0 to 2.3)17.7 (13.8 to 21.7)
Hour 240.8 (0.0 to 2.3)30.9 (26.2 to 35.7)
Hour 360.8 (0.0 to 2.3)44.0 (38.9 to 49.1)
Hour 482.3 (0.0 to 4.9)50.1 (45.0 to 55.3)
Day 70.8 (0.0 to 2.3)61.0 (55.9 to 66.0)
Day 140.0 (0.0 to 0.0)30.5 (25.6 to 35.3)
Day 210.0 (0.0 to 0.0)4.6 (2.4 to 6.9)
Day 280.0 (0.0 to 0.0)1.9 (0.5 to 3.3)
Day 351.5 (0.0 to 3.7)1.4 (0.2 to 2.5)
Day 430.0 (0.0 to 0.0)0.8 (0.0 to 1.8)
SecondaryPercentage of Participants With ≥2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown Over Time [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Percentage of participants with at least a 2-grade improvement from Baseline on the Facial Wrinkle Scale (FWS) according to investigator assessment of glabellar lines (GL) severity at maximum frown over time are reported. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 12, 24, 36, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind period)
Reported as:
Number · percentage of participants
Percentage of Participants With ≥2-grade Improvement From Baseline on the FWS According to Investigator Assessment of GL Severity at Maximum Frown Over Time [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Hour 81.5 (0.0 to 3.7)10.9 (7.7 to 14.1)
Hour 120.8 (0.0 to 2.3)18.6 (14.5 to 22.6)
Hour 240.8 (0.0 to 2.3)36.5 (31.5 to 41.4)
Hour 360.8 (0.0 to 2.3)53.3 (48.1 to 58.4)
Hour 480.8 (0.0 to 2.3)61.7 (56.6 to 66.7)
Day 70.8 (0.0 to 2.3)72.1 (67.5 to 76.7)
Day 140.0 (0.0 to 0.0)32.8 (27.9 to 37.7)
Day 210.0 (0.0 to 0.0)5.4 (3.0 to 7.7)
Day 280.0 (0.0 to 0.0)1.1 (0.0 to 2.2)
Day 350.0 (0.0 to 0.0)0.3 (0.0 to 0.8)
Day 430.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
SecondaryTime to Return to Baseline FWS According to Participant Assessment of FWS at Maximum Frown After Achieving Responder Definition on Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Time to return to Baseline (Baseline criterion of Moderate or Severe) on the Facial Wrinkle Scale (FWS) according to participant assessment of FWS at maximum frown after achieving responder definition on Day 7 is reported. Responder definition was a rating of None or Mild on the FWS. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. For those who maintained their response, censoring occurred at the latest visit during the treatment period for which FWS was available.

Time frame:
From Baseline to Day 43 (Double-blind Period)
Reported as:
Median · days
Time to Return to Baseline FWS According to Participant Assessment of FWS at Maximum Frown After Achieving Responder Definition on Day 7 [European Union Regulatory Agencies]
daysPlaceboAGN-151586
Time to Return to Baseline FWS According to Participant Assessment of FWS at Maximum Frown After Achieving Responder Definition on Day 7 [European Union Regulatory Agencies]28.0 (15 to 43)21.0 (8 to 50)
SecondaryTime to Return to Baseline FWS According to Investigator Assessment of FWS at Maximum Frown After Achieving Responder Definition on Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] Time to return to Baseline (Baseline criterion of Moderate or Severe) on the Facial Wrinkle Scale (FWS) according to investigator assessment of FWS at maximum frown after achieving responder definition on Day 7 is reported. Responder definition was a rating of None or Mild on the FWS. Assessments were performed using the 4-grade Facial Wrinkle Scale (FWS), where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. For those who maintained their response, censoring occurred at the latest visit during the treatment period for which FWS was available.

Time frame:
From Baseline to Day 43 (Double-blind Period)
Reported as:
Median · days
Time to Return to Baseline FWS According to Investigator Assessment of FWS at Maximum Frown After Achieving Responder Definition on Day 7 [European Union Regulatory Agencies]
daysPlaceboAGN-151586
Time to Return to Baseline FWS According to Investigator Assessment of FWS at Maximum Frown After Achieving Responder Definition on Day 7 [European Union Regulatory Agencies]15.0 (15 to 15)21.0 (8 to 50)
SecondaryPercentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL Over Time [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The FLSQ is a validated measure that assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the participant perspective. Participants assessed their overall satisfaction with their glabellar lines using a 5-point verbal descriptor scale (VDS): very dissatisfied, mostly dissatisfied, neither dissatisfied nor satisfied, mostly satisfied, and very satisfied. The percentage of participants mostly satisfied or very satisfied is reported. Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Hours 8, 24, and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Mostly Satisfied or Very Satisfied on the Facial Lines Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 (Overall Satisfaction) for GL Over Time [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Hour 814.3 (8.2 to 20.4)33.1 (28.3 to 38.0)
Hour 2416.2 (9.8 to 22.5)58.7 (53.6 to 63.7)
Hour 488.5 (3.7 to 13.2)71.4 (66.7 to 76.0)
Day 74.6 (1.0 to 8.3)76.9 (72.5 to 81.2)
Day 145.8 (1.7 to 10.0)69.9 (65.1 to 74.7)
Day 212.5 (0.0 to 5.2)61.4 (56.3 to 66.5)
Day 284.7 (0.9 to 8.4)56.1 (50.9 to 61.2)
Day 353.8 (0.5 to 7.2)58.3 (53.2 to 63.4)
Day 434.8 (1.1 to 8.6)58.1 (52.9 to 63.4)
SecondaryPercentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 10 (Look Angry) for GL at Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Participants answered FLO-11 Item 10 (Look Angry). Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 10 (Look Angry) for GL at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 10 (Look Angry) for GL at Day 7 [European Union Regulatory Agencies]5.6 (1.6 to 9.7)54.5 (49.2 to 59.7)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 48.8 · 95% CI 42.2 to 55.4Difference: AGN-151586 - Placebo
SecondaryPercentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 5 (Look Less Attractive) for GL at Day 7 [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The Facial Lines Outcomes (FLO-11) Questionnaire is an 11-item validated measure that assesses appearance-related psychological impacts of glabellar lines (GL) from the participant's perspective. Items 1-10 are assessed on an 11-point numeric rating scale that ranges from 0 (Not at all) to 10 (Very much), with higher scores indicating negative impact. Item 11 is scored in the reverse direction. Participants answered FLO-11 Item 5 (Look Less Attractive). Percentages are rounded off to nearest single decimal.

Time frame:
Baseline, Day 7 (Double-blind Period)
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 5 (Look Less Attractive) for GL at Day 7 [European Union Regulatory Agencies]
percentage of participantsPlaceboAGN-151586
Percentage of Participants With a ≥ 4-point Improvement From Baseline in FLO-11 Item 5 (Look Less Attractive) for GL at Day 7 [European Union Regulatory Agencies]3.9 (0.5 to 7.3)48.1 (42.9 to 53.3)
Statistical analysis
  • Placebo vs AGN-151586 · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was based on Cochran-Mantel-Haenszel (CMH) test stratified by investigator site, toxin use history (for aesthetic purposes), and baseline Facial Wrinkle Scale score at maximum frown after using multiple imputation for missing data.) · Rate difference: 44.2 · 95% CI 38.0 to 50.4Difference: AGN-151586 - Placebo
SecondaryMean Global Assessment of Change in Glabellar Lines (GAC-GL) at Maximum Frown Over Time [European Union Regulatory Agencies]

\[Secondary endpoint for European Union regulatory agencies\] The GAC-GL Questionnaire assesses the appearance of the participant's GL "now" in comparison with their perspective before treatment. Participants assessed the change in their glabellar lines at maximum frown using a 7-point verbal descriptor scale (VDS): very much improved, much improved, minimally improved, no change, minimally worse, much worse, and very much worse, ranging from 3 to -3. Positive changes indicate improvement, 0 no change, and negative changes indicate worsening.

Time frame:
Hours 24 and 48, Days 7, 14, 21, 28, 35, and 43 (Double-blind Period)
Reported as:
Least squares mean · units on a scale
Mean Global Assessment of Change in Glabellar Lines (GAC-GL) at Maximum Frown Over Time [European Union Regulatory Agencies]
units on a scalePlaceboAGN-151586
Hour 240.2 ± 0.101.4 ± 0.07
Hour 480.1 ± 0.091.9 ± 0.06
Day 70.1 ± 0.082.2 ± 0.06
Day 140.1 ± 0.101.5 ± 0.07
Day 210.1 ± 0.100.5 ± 0.07
Day 280.1 ± 0.100.2 ± 0.07
Day 350.1 ± 0.100.0 ± 0.07
Day 430.1 ± 0.090.0 ± 0.06

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the time of informed consent to the end of the study. The median time on follow-up was 85 days for the Double-blind Placebo and AGN-151586 groups as well as the Open-label Placebo/AGN-151586 and AGN-151586/AGN-151586 groups, 50 days for the Placebo/None group, and 53 days for the AGN-151586/None group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/156 (0%)1/156 (0.6%)9/156 (5.8%)
AGN-1515860/482 (0%)3/482 (0.6%)31/482 (6.4%)
Placebo/None0/3 (0%)0/3 (0%)0/3 (0%)
Placebo/AGN-1515860/145 (0%)0/145 (0%)8/145 (5.5%)
AGN-151586/None0/17 (0%)0/17 (0%)0/17 (0%)
AGN-151586/AGN-1515860/437 (0%)1/437 (0.2%)14/437 (3.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
INVASIVE DUCTAL BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1560/4820/30/1450/170/437
PYELONEPHRITISInfections and infestations0/1560/4820/30/1450/171/437
APPENDICITISInfections and infestations0/1561/4820/30/1450/170/437
PNEUMONIAInfections and infestations0/1561/4820/30/1450/170/437
HYPOCALCAEMIAMetabolism and nutrition disorders0/1561/4820/30/1450/170/437
Most frequent other events
Most frequent other events
EventPlaceboAGN-151586Placebo/NonePlacebo/AGN-151586AGN-151586/NoneAGN-151586/AGN-151586
HEADACHENervous system disorders9/15631/4820/38/1450/1714/437

Baseline characteristics

Intent to Treat Population: all randomized participants, analyzed according to the treatment groups to which they were randomized

Age, Continuous
Age, Continuous(years)PlaceboAGN-151586Total
Mean47.6 ± 12.4847.1 ± 12.7547.2 ± 12.68
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAGN-151586Total
Female137429566
Male195372
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAGN-151586Total
Hispanic or Latino144963
Not Hispanic or Latino142433575
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAGN-151586Total
American Indian or Alaska Native101
Asian31619
Native Hawaiian or Other Pacific Islander224
Black or African American52126
White142432574
More than one race31114
Unknown or Not Reported000
Facial Wrinkle Scale (FWS) at Maximum Frown - Participant
Facial Wrinkle Scale (FWS) at Maximum Frown - Participant(Participants)PlaceboAGN-151586Total
0 = None000
1 = Mild134
2 = Moderate41149190
3 = Severe114330444
Facial Wrinkle Scale (FWS) at Maximum Frown - Investigator
Facial Wrinkle Scale (FWS) at Maximum Frown - Investigator(Participants)PlaceboAGN-151586Total
0 = None000
1 = Mild123
2 = Moderate41149190
3 = Severe114331445
08

Study locations

38 sites
  • Total Skin and Beauty Derm Ctr /ID# 232378
    Birmingham, Alabama 35205, United States
  • Clinical Testing of Beverly Hills /ID# 233195
    Encino, California 91436-2124, United States
  • Westside Aesthetics /ID# 232443
    Los Angeles, California 90025-1708, United States
  • The Research Center at The Maas Clinic /ID# 241262
    San Francisco, California 94115-1809, United States
  • Center for Dermatology and Dermatologic Surgery /ID# 232315
    Washington, District of Columbia 20037-1445, United States
  • Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232439
    Boca Raton, Florida 33431-6465, United States
  • Dermatology Clinic & Cosmetic Center /ID# 244295
    Baton Rouge, Louisiana 70808-4691, United States
  • Delricht Research /ID# 241253
    New Orleans, Louisiana 70115, United States
  • Skincare Physicians /ID# 233938
    Chestnut Hill, Massachusetts 02467, United States
  • BOYD Beauty Birmingham /ID# 232383
    Birmingham, Michigan 48009-6301, United States
  • Skin Search of Rochester Inc. /ID# 232549
    Rochester, New York 14623, United States
  • Aesthetic Solutions /ID# 232389
    Chapel Hill, North Carolina 27517-9901, United States
  • Aventiv Research Dublin /ID# 233936
    Dublin, Ohio 43016, United States
  • KGL Skin Study Center, LLC /ID# 233549
    Newtown Square, Pennsylvania 19073-2228, United States
  • Nashville Center for Laser and Facial Surgery /ID# 242535
    Nashville, Tennessee 37203-1513, United States
  • Westlake Dermatology & Cosmetic Surgery - Westlake /ID# 232410
    Austin, Texas 78746-4720, United States
  • Dallas Plastic Surgery Institute /ID# 232328
    Dallas, Texas 75231, United States
  • Austin Institute for Clinical Research at SBA Dermatology /ID# 232316
    Houston, Texas 77056-4129, United States
  • Beacon Dermatology Inc /ID# 233227
    Calgary, Alberta T3E 0B2, Canada
  • Alberta DermaSurgery Centre /ID# 241172
    Edmonton, Alberta T6G 1C3, Canada
  • Dr. Wei Jing Loo Medicine Prof /ID# 241863
    London, Ontario N6H 5L5, Canada
  • Erevna Innovations Inc. /ID# 239592
    Westmount, Quebec H3C 1Z3, Canada
  • Studienzentrum Theatiner46 /ID# 241185
    Muenchen, Bayern 80333, Germany
  • Rosenpark Research /ID# 232391
    Darmstadt, Hessen 64283, Germany
  • Privatpraxis Dr. Hilton & Partner /ID# 232392
    Duesseldorf, Nordrhein-Westfalen 40212, Germany
  • Noahklinik GmbH /ID# 241184
    Kassel, 34117, Germany
  • Hautok and Hautok-cosmetics /ID# 232393
    Muenchen, 80333, Germany
  • Privatpraxis fuer Dermatologie und Aesthetik /ID# 241544
    Muenchen, 80539, Germany
  • MediCorium Zentrum fuer Dermatologie und Aesthetik /ID# 241186
    Oberursel, 61440, Germany
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 244708
    Szeged, Csongrad 6725, Hungary
  • Derm-Surg Kft. /ID# 244709
    Kaposvár, Somogy 7400, Hungary
  • Derma-B Egeszsegugyi es Szolgaltato Kft. /ID# 244706
    Debrecen, 4031, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 244707
    Pecs, 7624, Hungary
  • Dermed Centrum Medyczne Sp. z o.o /ID# 242972
    Lodz, Lodzkie 90-265, Poland
  • Instytut Zdrowia Dr Boczarska-Jedynak Sp. Z O.O. Sp.K. /Id# 242990
    Oswiecim, Malopolskie 32-600, Poland
  • Clinical Research Group Sp. z o.o. /ID# 242988
    Warsaw, Mazowieckie 01-142, Poland
  • High-Med Przychodnia Specjalistyczna /ID# 242973
    Warszawa, Mazowieckie 01-817, Poland
  • Novo-Med Zielinski i Wspolnicy Spolka Jawna /ID# 242986
    Katowice, Slaskie 40-650, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Mar 2023, 12 months.

Results were first posted in May 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Feb 21, 2022
StartActual
Mar 16, 2022
Primary completionActual
Mar 17, 2023
CompletionActual
Mar 17, 2023
Results first posted
May 24, 2024
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05248867
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Mar 16, 2022
Primary completion
Mar 17, 2023
Completion
Mar 17, 2023
Results posted
May 24, 2024
Last update
May 24, 2024

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: trenibotulinumtoxinE

Start the discussion